RxDoctor Payments Data

Monica Patel, MD

Ophthalmology · Jackson Heights, NYNPI 1295070910

Payments from drug & device makers

$9,594in general payments, 2019–2025

Across 92 payments — averaging $104.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$7K
  • Bausch & Lomb Americas Inc.$1K
  • Harrow Eye, LLC$346
  • Tarsus Pharmaceuticals, Inc.$334
  • Alcon$227
  • Mallinckrodt Hospital Products Inc.$226
  • plus $764 from 8 others

What the payments were for

  • Speaking & faculty fees$6,03063%
  • Food & beverage$3,39035%
  • Education$1742%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,594 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$121,584
Medicare patients
164
Services billed
1,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast178$125,663
RestasisCyclosporine140$99,893
CequaCyclosporine68$42,260
VevyeCyclosporine20$30,145
VyzultaLatanoprostene Bunod85$27,357
LumiganBimatoprost84$21,046
MieboPerfluorohexyloctane/Pf23$19,429
Timolol Maleate358$15,340
RhopressaNetarsudil Mesylate44$14,606
RocklatanNetarsudil Mesylat/Latanoprost30$12,940
CombiganBrimonidine Tartrate/Timolol47$9,128
Cyclosporine27$9,115
Prednisolone Acetate209$8,580
SimbrinzaBrinzolamide/Brimonidine Tart39$8,172
Latanoprost918$6,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$1,033$172,449286 claims
Sun Pharmaceutical Industries Inc.Cequa$6,664$42,26068 claims
Harrow Eye, LLCVevye$346$30,14520 claims
AlconSimbrinza$227$8,17239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Jackson Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →